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ABSTRACT PAGE 
 
       Effective diagnosis and treatment of breast cancer rely on a precise and detailed 
understanding of the cellular-molecular alterations that give rise to an oncogenic phenotype. With 
the advent of new imaging technologies investigators have begun to follow mammary tumor 
development in vivo and noninvasively with high resolution and sensitivity. Continued progress 
requires combining molecular biology and imaging with the goal of imaging the metabolism of 
specific tumor-related molecules.  As a result, we have developed a novel small animal gamma 
camera that is capable of detecting low levels (0.52 MBq, 14 uCi) of radioiodine (125I). The 
dynamic uptake of 125I through the sodium iodide symporter (NIS) was used to detect the 
progression of spontaneous mammary tumors in the mouse mammary tumor virus (MMTV) 
model as well as the transgenic animal model expressing the polyoma middle T oncoprotein 
(PyVT). Based on whole mount immunohistochemistry, NIS protein expression correlates with the 
gamma camera images of 125I, which is also a promising radiotracer for detecting small, non-
palpable tumors (3 mm). Additionally, gamma imaging was capable of identifying PyVT mice from 
their wild type littermates based upon their ability to accumulate 125I in nulliparous mammary 
glands as early as 5 weeks of age. MMTV tumors are classified into three groups based on their 
unique 125I distribution that is correlated with tumor size, but not propagation rate. Differences in 
125I uptake gain (or loss) are dynamic especially during early dose administration. Finally, 
mammary glands show differences in uptake pattern when a tumor is present.   
       Taken together, these results suggest that radioiodide imaging is a promising in vivo method 
for monitoring the changes associated with tumor development such as changes of tumor size, 
pattern, and aspects of gene-specific metabolism over both short and long durations. Our results 
also indicate that the classifiable heterogeneity present in dynamic gamma camera images may 
correlate with specific patterns or signatures of gene expression that, in turn, indicate tumor 
subtype and progression.  These data may allow investigators to develop an effective and 
sensitive system of in vivo imaging of molecules and metabolism that reflect the molecular 
signature of a tumor in real time.  Our system may provide a means for early detection, ideally 
even a precancerous state before malignancy develops, and a method to assess the overall state 
of a tumor with the goal of predicting the best therapeutic regime and following the efficacy of the 
therapy in real time by examining specific molecular targets. 
 
 
 
 
 
 
 
